A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
ImmuneOncia Therapeutics Inc.
ImmuneOncia Therapeutics Inc.
Sun Yat-sen University
Dren Bio
Thomas Jefferson University
National Cancer Institute (NCI)
Beijing Tongren Hospital
International Extranodal Lymphoma Study Group (IELSG)
Bristol-Myers Squibb
Fudan University
Beijing Tongren Hospital
M.D. Anderson Cancer Center
Bristol-Myers Squibb
CStone Pharmaceuticals
The First Affiliated Hospital with Nanjing Medical University
City of Hope Medical Center
Ruijin Hospital
Antengene Corporation
Mayo Clinic
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Case Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Baylor College of Medicine
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Peking University Cancer Hospital & Institute
Memorial Sloan Kettering Cancer Center
The First Affiliated Hospital with Nanjing Medical University
Washington University School of Medicine
Ruijin Hospital
Peking Union Medical College Hospital
Ruijin Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
BeiGene
Ruijin Hospital
Ruijin Hospital
Kura Oncology, Inc.
Sun Yat-sen University
University of Aarhus
The Thai Lymphoma Study Group
Northwestern University
City of Hope Medical Center
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
UNICANCER
Wake Forest University Health Sciences
Stanford University
Stanford University